Deterioration of Disease and Acute Episodes Do not initiate Trelegy Ellipta in patients with rapidly deteriorating or potentially life-threatening episodes of COPD or asthma; use in this setting ...

Trelegy Ellipta got its first US approval in September as a daily long-term maintenance therapy for chronic obstructive pulmonary disease (COPD). Trelegy was approved in Europe last week in COPD ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

Anoro Ellipta (umeclidinium and vilanterol) is a brand-name inhaler that’s prescribed for COPD. Anoro Ellipta has ... your risk of side effects from the medication. Examples of antifungal ...

Around 15,000 Kiwis - a number of them Māori and Pasifika - living with chronic obstructive pulmonary disease (COPD), the ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Drug companies have until February 28, 2025, to decide on participation. The list features key medications like Trelegy Ellipta, Xtandi, and Pomalyst. This image is AI-generated and does not depict ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14) compared ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...